MetaVia Inc. (Nasdaq: MTVA) reported financial results for the third quarter ended September 30, 2026, and provided an update on its clinical pipeline. For the three months ended September 30, 2026, the company reported a net loss of $4.6 million, or $0.69 per share, compared to a net loss of $3.4 million, or $1.52 per share, in the prior year period. Research and development expenses for the quarter were approximately $2.6 million, an increase of approximately $0.7 million compared to the same period in 2025, driven by higher direct costs related to the development of DA-1726. General and administrative expenses were approximately $2.1 million for the quarter, up from $1.6 million in the prior year.
The company highlighted positive interim data from its Phase 1 Part 3B study of DA-1726, a novel oxyntomodulin analog and dual GLP-1/glucagon receptor agonist. At Day 109, the data demonstrated a placebo-adjusted reduction of 68.1% in liver fat and a 13.5% reduction in body weight. All five participants with baseline steatosis achieved an MRI-PDFF score below 5%. Additional interim data showed a statistically significant 1.47 mg/dL placebo-adjusted reduction in uric acid after 16 weeks of treatment. Based on these results, MetaVia plans to initiate a 48-week Phase 2 study in up to 150 subjects with Metabolic Dysfunction and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), targeting the second half of 2027.
In other corporate news, MetaVia appointed Sarah Browne, M.D., as Chief Medical Officer in October 2026. The company also announced plans to advance vanoglipel, a GPR119 agonist, in combination with resmetirom for Metabolic Dysfunction-Associated Steatohepatitis (MASH). A Phase 2a proof-of-concept study is targeted to begin in the first half of 2027. As of September 30, 2026, MetaVia held $8.8 million in cash and cash equivalents.
